Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIA-2291 in Carotid Stenosis
NCT00352417Phase 2Completed
- Sponsor
- Tallikut Pharmaceuticals, Inc.
- Start
- Jul 2006
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis and carotid artery stenosis comparing VIA-2291 with Placebo (2 arms). Primary endpoint: Percent Cross-sectional Area of Macrophages in Plaque Tissue at 12 weeks. Started Jul 2006; status: completed.
02
Drugs
Atreleuton
03
Conditions
atherosclerosiscarotid artery stenosis
Beyond the preview
Go deeper on NCT00352417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00352417.